Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Nektar Therapeutics (NASDAQ: NKTR) closed at $0.95 in the last session, down -0.21% from day before closing price of $0.95. In other words, the price has decreased by -$0.21 from its previous closing price. On the day, 1.1 million shares were traded. NKTR stock price reached its highest trading level at $0.9649 during the session, while it also had its lowest trading level at $0.907.
Ratios:
We take a closer look at NKTR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 4.22 whereas as Long-Term Debt/Eq ratio is at 3.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 10, 2024, initiated with a Buy rating and assigned the stock a target price of $6.50.
On November 04, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $7.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 23 ’24 when Wilson Mark Andrew sold 33,402 shares for $0.90 per share. The transaction valued at 30,062 led to the insider holds 351,892 shares of the business.
Wilson Mark Andrew sold 16,560 shares of NKTR for $14,738 on Dec 24 ’24. The Chief Legal Officer now owns 335,332 shares after completing the transaction at $0.89 per share. On Dec 24 ’24, another insider, Wilson Mark Andrew, who serves as the Officer of the company, bought 16,560 shares for $0.89 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 175087536 and an Enterprise Value of 136683808. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.88 while its Price-to-Book (P/B) ratio in mrq is 3.58. Its current Enterprise Value per Revenue stands at 1.468 whereas that against EBITDA is -1.05.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.48. The 50-Day Moving Average of the stock is -17.61%, while the 200-Day Moving Average is calculated to be -24.95%.
Shares Statistics:
According to the various share statistics, NKTR traded on average about 1.78M shares per day over the past 3-months and 1414620 shares per day over the past 10 days. A total of 184.46M shares are outstanding, with a floating share count of 177.69M. Insiders hold about 3.67% of the company’s shares, while institutions hold 74.38% stake in the company. Shares short for NKTR as of 1734048000 were 4396857 with a Short Ratio of 2.47, compared to 1731628800 on 5126494. Therefore, it implies a Short% of Shares Outstanding of 4396857 and a Short% of Float of 3.05.
